MYO Health completed the Value Dossier of Epidiolex® for market access in the United States


MYO Health completed and submitted the Value Dossier of Epidiolex® for market access in the United States, to its partner and primary contractor, Strategic Health Resources. Epidiolex® received FDA approval in the summer of 2018, becoming the first FDA-approved drug indicated for the treatment of Dravet syndrome. We are particularly happy to have successfully delivered the Value Dossier of this groundbreaking new drug, which is an important milestone in the treatment of one of the most debilitating epileptic syndromes in children.